Alzamend Neuro, Inc.
ALZN
$0.67
-$0.04-5.63%
NASDAQ
| 01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | 01/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -4.23M | -5.90M | -7.39M | -9.95M | -12.40M |
| Total Depreciation and Amortization | 50.80K | 50.80K | 50.80K | 50.80K | 43.40K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 335.20K | 440.50K | 677.50K | 956.30K | 1.37M |
| Change in Net Operating Assets | -3.47M | -2.50M | 638.50K | 670.60K | 1.91M |
| Cash from Operations | -7.31M | -7.91M | -6.03M | -8.27M | -9.08M |
| Capital Expenditure | -90.00K | -90.00K | -90.00K | -147.20K | -147.20K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -90.00K | -90.00K | -90.00K | -147.20K | -147.20K |
| Total Debt Issued | 300.00K | 300.00K | 300.00K | 300.00K | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 2.13M | 2.41M | 1.25M | 1.25M | 982.80K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | 8.04M | 9.19M | 4.06M | 2.10M | 1.15M |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 10.47M | 11.90M | 5.62M | 3.65M | 2.13M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 3.08M | 3.89M | -501.40K | -4.76M | -7.09M |